3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
10
fludarabine
7
pomalidomide
6
Dexamethasone
6
pembrolizumab
5
daratumumab
5
Rituximab
4
obinutuzumab
3
glofitamab
3
fludarabine phosphate
3
abemaciclib
3
Nivolumab
3
Melphalan
3
Etoposide
3
Bortezomib
3
venetoclax
2
tocilizumab
2
palbociclib
2
cemiplimab
2
carfilzomib
2
Temozolomide
2
Oxaliplatin
2
Mesna
2
Letrozole
2
Lenalidomide
2
Injections
2
Immunotherapy, Adoptive
2
Gemcitabine
2
Biopsy
2
zanubrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.